{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:36:40Z","timestamp":1786739800071,"version":"build-2736575974"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,9]]},"abstract":"\n Purpose:<\/jats:title>\n \n To compare the efficacy and the tolerability of preservative-free Tafluprost 0.0015% (TP)\n vs<\/jats:italic>\n Latanoprost 0.005% (LP) in patients with primary open-angle glaucoma (POAG).\n <\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n Prospective, randomized, crossover study included patients with early POAG attending the outpatient clinic from July 2019 to February 2020. Patients were divided into 2 groups: group A included patients receiving TP and group B receiving LP. After 2 months, treatment was stopped for 1 month (washout period) then drops were switched between the groups for further 2 months. Intraocular pressure (IOP) was recorded at baseline and monthly until 5 months. Efficacy was measured by the IOP reduction at the end of each treatment period. Tolerability was assessed both subjectively (questionnaire on ocular comfort) and objectively (ocular findings) at the end of each period.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n A total of 30 patients were allocated into two groups (15 patients each). There was no statistically significant difference between the 2 groups in baseline clinical examinations. All the eyes in both groups achieved IOP reduction >20% compared to baseline values, with no statistically significant difference in between. Corneal erosions and conjunctival hyperemia were significantly higher in LP-treated eyes throughout the study, regardless of the sequence. Tear break-up time scores significantly worsened after LP at the 2\n nd<\/jats:sup>\n and 5\n th<\/jats:sup>\n month (\n P<\/jats:italic>\n < 0.001and\n P<\/jats:italic>\n = 0.026 respectively) but not after TP treatment (\n P<\/jats:italic>\n = 0.719 and\n P<\/jats:italic>\n = 0.164). Significant exacerbation in all patients\u2019 symptoms was noticed on switching from TP to LP.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n Tafluprost was proved to exhibit a comparable effect on IOP control in POAG patients, as Latanoprost drops resulted in marked alleviation in both subjective and objective ocular discomfort manifestations.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/ijo.ijo_165_21","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T23:07:16Z","timestamp":1630537636000},"page":"2475-2480","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Crossover randomized study comparing the efficacy and tolerability of preservative-free Tafluprost 0.0015% to Latanoprost 0.005% in patients with primary open-angle glaucoma"],"prefix":"10.4103","volume":"69","author":[{"given":"Sherein M","family":"Hagras","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Mansoura University, Faculty of Medicine, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar KH","family":"Al-Duwailah","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Farwanyia Hospital, Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona A","family":"Nassief","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Tanta University, Faculty of Medicine, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameera G","family":"Abdelhameed","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Mansoura University, Faculty of Medicine, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,8,25]]},"reference":[{"key":"B1-20240828","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/S0161-6420(96)30407-7","article-title":"Latanoprost, a prostaglandin analogue, for glaucoma treatment:Efficacy and safety after 1 year of treatment in 198 patients","volume":"103","author":"Camras","year":"1996","journal-title":"Ophthalmology"},{"key":"B2-20240828","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/IJG.0000000000000279","article-title":"The impact of glaucoma medications on corneal wound healing","volume":"25","author":"Pinheiro","year":"2016","journal-title":"J Glaucoma"},{"key":"B3-20240828","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/112067210701700311","article-title":"Ocular symptoms and signs with preserved and preservative-free glaucoma medications","volume":"17","author":"Jaenen","year":"2007","journal-title":"Eur J Ophthalmol"},{"key":"B4-20240828","first-page":"2131","article-title":"Preservative toxicity in glaucoma medication:Clinical evaluation of benzalkonium chloride-free 0.5% timolol eye drops","volume":"7","author":"Rosin","year":"2013","journal-title":"Clin Ophthalmol"},{"key":"B5-20240828","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/IJG.0000000000000020","article-title":"Safety and efficacy of benzalkonium chloride-optimized tafluprost in Japanese glaucoma patients with existing superficial Punctate Keratitis","volume":"24","author":"Suzuki","year":"2015","journal-title":"J Glaucoma"},{"key":"B6-20240828","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1089\/jop.2014.0104","article-title":"Comparison of the toxicity profile of benzalkonium chloride-preserved tafluprost and SofZia-preserved travoprost applied to the ocular surface","volume":"31","author":"Kanamoto","year":"2015","journal-title":"J Ocul Pharmacol Ther"},{"key":"B7-20240828","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s12325-010-0070-1","article-title":"Effects of benzalkonium chloride preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells","volume":"27","author":"Ammar","year":"2010","journal-title":"Adv Ther"},{"key":"B8-20240828","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1755-3768.2012.02565.x","article-title":"Effects of SofZia-preserved travoprost and benzalkonium chloride-preserved latanoprost on the ocular surface \u2013A multicenter randomized single-masked study","volume":"91","author":"Aihara","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"B9-20240828","first-page":"71","article-title":"Efficacy and tolerability of preservative-free tafluprost 0.0015% in Korean patients with glaucoma","volume":"8","author":"Hwang","year":"2014","journal-title":"Clin Ophthalmol"},{"key":"B10-20240828","first-page":"513","article-title":"Preclinical pharmacology of latanoprost, a phenyl-substituted PGF2a analogue","volume":"23","author":"Stjernschantz","year":"1995","journal-title":"Adv Prostaglandin Thromboxane Leuket Res"},{"key":"B11-20240828","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/01.ijg.0000212214.18018.41","article-title":"An evaluation of the rate of nonresponders to latanoprost therapy","volume":"15","author":"Rossetti","year":"2006","journal-title":"J Glaucoma"},{"key":"B12-20240828","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.exer.2003.12.007","article-title":"Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug","volume":"78","author":"Takagi","year":"2004","journal-title":"Exp Eye Res"},{"key":"B14-20240828","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12886-017-0453-z","article-title":"Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients:A prospective crossover study","volume":"17","author":"Lee","year":"2017","journal-title":"BMC Ophthalmol"},{"key":"B15-20240828","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1097\/ICO.0b013e318294b0c0","article-title":"Psychometric properties and validation of the Standard Patient Evaluation of Eye Dryness questionnaire","volume":"32","author":"Ngo","year":"2013","journal-title":"Cornea"},{"key":"B17-20240828","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15761\/NFO.1000202","article-title":"phase III, randomized, clinical, crossover study to evaluate the non-inferiority of an ophthalmic solution of preservative-free latanoprost at 0.005% in patients with primary open-angle glaucoma","volume":"4","author":"Sanchez-castellanos","year":"2018","journal-title":"New Front Ophthalmol"},{"key":"B18-20240828","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1136\/bjophthalmol-2012-303026","article-title":"Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension","volume":"97","author":"Konstas","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"B19-20240828","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1755-3768.2010.01862.x","article-title":"Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension:24-month results of a randomized, double-masked phase III study","volume":"88","author":"Uusitalo","year":"2010","journal-title":"Acta Ophthalmol"},{"key":"B20-20240828","first-page":"3190684","article-title":"Washout duration of prostaglandin analogues:A systematic review and meta-analysis","volume":"27","author":"Diaconita","year":"2018","journal-title":"J Ophthalmol"},{"key":"B21-20240828","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2147\/OPTH.S91402","article-title":"Benefits of switching from latanoprost to preservative-free tafluprost eye drops:A meta-analysis of two Phase IIIb clinical trials","volume":"10","author":"Uusitalo","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"B22-20240828","first-page":"1319628","article-title":"Comparison of efficacy and ocular surface disease index score between bimatoprost, latanoprost, travoprost, and tafluprost in glaucoma patients","volume":"7","author":"El Hajj Moussa","year":"2018","journal-title":"J Ophthalmol"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_165_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:33:26Z","timestamp":1786736006000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_165_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,25]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_165_21","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,25]]},"assertion":[{"value":"2021-01-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}